{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:10:46Z","timestamp":1780524646028,"version":"3.54.1"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22HA1004"],"award-info":[{"award-number":["22HA1004"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jiac.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T22:19:31Z","timestamp":1728166771000},"page":"102535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic drug monitoring of azole antifungal agents"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5659-6507","authenticated-orcid":false,"given":"Yukihiro","family":"Hamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2702-5841","authenticated-orcid":false,"given":"Yusuke","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.10.003_bib1","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.3314\/mmj.16-00010","article-title":"Executive summary of Japanese domestic guidelines for management of deep-seated mycosis 2014","volume":"57","author":"Kohno","year":"2016","journal-title":"Med Mycol J"},{"key":"10.1016\/j.jiac.2024.10.003_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.003_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiac.2024.10.003_bib4","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","article-title":"Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"44","author":"Takesue","year":"2022","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.jiac.2024.10.003_bib5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S2666-5247(24)00042-9","article-title":"The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation","volume":"5","author":"Casalini","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jiac.2024.10.003_bib6","article-title":"Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens","volume":"62","author":"Morrissey","year":"2024","journal-title":"Med Mycol"},{"key":"10.1016\/j.jiac.2024.10.003_bib7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10156-011-0363-6","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis","volume":"18","author":"Hamada","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.003_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/FTD.0000000000000952","article-title":"Antifungal drugs TDM: trends and update","volume":"44","author":"Kably","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2024.10.003_bib11","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2165\/11596540-000000000-00000","article-title":"Triazole antifungal agents in invasive fungal infections: a comparative review","volume":"71","author":"Lass-Fl\u00f6rl","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2024.10.003_bib12","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","article-title":"Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation","volume":"26","author":"G\u00f3mez-L\u00f3pez","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2024.10.003_bib13","first-page":"17","article-title":"Pharmacokinetic evaluation of fluconazole in healthy volunteers","volume":"42","author":"Shiba","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2024.10.003_bib14","first-page":"654","article-title":"A clinical study of fluconazole-granules and -injectable in pediatric patients with deep-seated mycoses","volume":"46","author":"Fujii","year":"1993","journal-title":"Jpn J Antibiot"},{"issue":"S3","key":"10.1016\/j.jiac.2024.10.003_bib15","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","article-title":"Pharmacokinetics and tissue penetration of fluconazole in humans","volume":"12","author":"Brammer","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.003_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.00474-06","article-title":"Association of Fluconazole area under the concentration-time curve\/MIC and dose\/MIC ratios with mortality in nonneutropenic patients with candidemia","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib17","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/AAC.00216-13","article-title":"Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints","volume":"57","author":"Sudan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1681\/ASN.V62242","article-title":"Pharmacokinetics of fluconazole in renal failure","volume":"6","author":"Berl","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jiac.2024.10.003_bib19","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1128\/AAC.00424-11","article-title":"Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets","volume":"55","author":"Patel","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients","volume":"15","author":"John","year":"2019","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.jiac.2024.10.003_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01554-20","article-title":"Optimization of fluconazole dosing for the prevention and treatment of invasive candidiasis based on the pharmacokinetics of fluconazole in critically ill patients","volume":"65","author":"Boonstra","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib22","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3390\/jof7110975","article-title":"Population pharmacokinetic analysis and dosing optimization of prophylactic fluconazole in Japanese patients with hematological malignancy","volume":"7","author":"Sakamoto","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.jiac.2024.10.003_bib23","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/AAC.00019-12","article-title":"Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia","volume":"56","author":"Shah","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1517\/14656566.1.2.287","article-title":"Itraconazole","volume":"1","author":"Pi\u00e9rard","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jiac.2024.10.003_bib25","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/323020","article-title":"Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS","volume":"33","author":"Caillot","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.003_bib26","doi-asserted-by":"crossref","first-page":"644","DOI":"10.11150\/kansenshogakuzasshi.85.644","article-title":"An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis","volume":"85","author":"Tomioka","year":"2011","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.jiac.2024.10.003_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12281-017-0287-4","article-title":"Update on therapeutic drug monitoring of antifungals for the prophylaxis and treatment of invasive fungal infections","volume":"11","author":"Schwartz","year":"2017","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.jiac.2024.10.003_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/jcp.50.6.477","article-title":"Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis","volume":"50","author":"Cartledge","year":"1997","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jiac.2024.10.003_bib29","first-page":"1","article-title":"SUBA-itraconazole in the treatment of systemic fungal infections","volume":"16","author":"Liu","year":"2024","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jiac.2024.10.003_bib30","first-page":"387","article-title":"Itraconazole: pharmacokinetics and indications","volume":"24","author":"Negroni","year":"1993","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jiac.2024.10.003_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib32","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1128\/AAC.37.10.2224","article-title":"Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations","volume":"37","author":"Hostetler","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jac\/40.6.753","article-title":"Therapeutic drug monitoring of systemic antifungal therapy","volume":"40","author":"Summers","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib34","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02353-20","article-title":"Variability of hydroxy-itraconazole in relation to itraconazole bloodstream concentrations","volume":"65","author":"Wiederhold","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib35","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1128\/AAC.00514-12","article-title":"Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus","volume":"56","author":"Tashiro","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/JCM.36.1.198-202.1998","article-title":"In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jiac.2024.10.003_bib37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.41.4.841","article-title":"In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens","volume":"41","author":"Radford","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3314\/jjmm.46.223","article-title":"Voriconazole-medical needs, evidence, potential for the future","volume":"46","author":"Shirasawa","year":"2005","journal-title":"Nihon Ishinkin Gakkai Zasshi"},{"key":"10.1016\/j.jiac.2024.10.003_bib39","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jiac.2024.10.003_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1365-2125.2003.01994.x","article-title":"Effect of food on the pharmacokinetics of multiple-dose oral voriconazole","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.003_bib41","first-page":"17","article-title":"Voriconazole monitoring in children with invasive fungal infections","volume":"20","author":"Tucker","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.jiac.2024.10.003_bib42","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/AAC.00032-15","article-title":"Achieving target voriconazole concentrations more accurately in children and adolescents","volume":"59","author":"Neely","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jiac.2015.09.008","article-title":"Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients","volume":"22","author":"Kato","year":"2016","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00955-18","article-title":"Therapeutic drug monitoring of voriconazole in children from a Tertiary Care Center in China","volume":"62","author":"Hu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib45","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/AAC.04093-14","article-title":"Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients","volume":"59","author":"Mori","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib46","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.31.6.731","article-title":"The disposition of voriconazole in mouse, rat, rabbit, Guinea pig, dog, and human","volume":"31","author":"Roffey","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jiac.2024.10.003_bib47","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1086\/377131","article-title":"Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients","volume":"37","author":"Lutsar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.003_bib48","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s10384-022-00907-2","article-title":"Multicenter prospective observational study of fungal keratitis in Japan: analyses of in vitro susceptibility tests for combinations of drugs","volume":"66","author":"Kimura","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jiac.2024.10.003_bib49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0009-9236(96)90214-3","article-title":"Genotyping of S-mephenytoin 4\u2032-hydroxylation in an extended Japanese population","volume":"60","author":"Kubota","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2024.10.003_bib50","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2024.10.003_bib51","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00228-016-2089-y","article-title":"Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis","volume":"72","author":"Li","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.003_bib52","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s15010-012-0322-x","article-title":"Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan","volume":"40","author":"Saito","year":"2012","journal-title":"Infection"},{"issue":"S1","key":"10.1016\/j.jiac.2024.10.003_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2125.2003.01997.x","article-title":"Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.003_bib54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jcph.605","article-title":"Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole","volume":"56","author":"Imamura","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.003_bib55","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s13318-019-00603-6","article-title":"Effect of gender and age on voriconazole trough concentrations in Italian adult patients","volume":"45","author":"Allegra","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jiac.2024.10.003_bib56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/1120009X.2020.1765604","article-title":"Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients","volume":"33","author":"Luo","year":"2021","journal-title":"J Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/2949681016666230830125358","article-title":"Stimulatory and inhibitory effects of steroid hormones and human cytochrome P450 (CYP) 3A inhibitors on cortisol 6\u03b2-hydroxylation catalyzed by CYP3A subfamilies","volume":"16","author":"Niwa","year":"2023","journal-title":"Drug Metab Bioanal Lett"},{"key":"10.1016\/j.jiac.2024.10.003_bib59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1053\/j.ajkd.2004.09.017","article-title":"Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients","volume":"45","author":"Peng","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2024.10.003_bib60","doi-asserted-by":"crossref","first-page":"e00507","DOI":"10.1128\/AAC.00507-18","article-title":"Effect of cumulative intravenous voriconazole dose on renal function in hematological patients","volume":"62","author":"Yasu","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jinf.2012.09.011","article-title":"Voriconazole hepatotoxicity in severe liver dysfunction","volume":"66","author":"Sol\u00eds-Mu\u00f1oz","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.jiac.2024.10.003_bib62","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/phar.2474","article-title":"Using Child-Pugh class to optimize voriconazole dosage regimens and improve safety in patients with liver cirrhosis: insights from a population pharmacokinetic model-based analysis","volume":"41","author":"Wang","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2024.10.003_bib63","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1248\/bpb.b23-00461","article-title":"Necessity for a system implementing therapeutic drug monitoring in outpatient settings based on the actual use of voriconazole using the national database of health insurance claims and specific health checkups of Japan: a descriptive epidemiological study","volume":"46","author":"Muraki","year":"2023","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jiac.2024.10.003_bib64","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib65","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12185-009-0296-3","article-title":"Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders","volume":"89","author":"Ueda","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jiac.2024.10.003_bib66","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1179\/1973947815Y.0000000057","article-title":"Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data","volume":"28","author":"Matsumoto","year":"2016","journal-title":"J Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib67","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.003_bib68","first-page":"739","article-title":"Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring","volume":"136","author":"Imhof","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.jiac.2024.10.003_bib69","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/jcpt.12817","article-title":"Impact of voriconazole plasma concentrations on treatment response in critically ill patients","volume":"44","author":"Ruiz","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jiac.2024.10.003_bib70","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/myc.13129","article-title":"Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: a multicentre study conducted in Japan","volume":"63","author":"Hamada","year":"2020","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2024.10.003_bib71","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1128\/AAC.47.10.3165-3169.2003","article-title":"In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model","volume":"47","author":"Andes","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib72","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/jac\/dku484","article-title":"Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic\/pharmacodynamic model--authors\u2019 response","volume":"70","author":"Siopi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib73","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib74","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00133-20","article-title":"Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib75","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/jof7040306","article-title":"Favorable effects of voriconazole trough concentrations exceeding 1 \u03bcg\/mL on treatment success and all-cause mortality: a systematic review and meta-analysis","volume":"7","author":"Hanai","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.jiac.2024.10.003_bib76","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1128\/AAC.01083-10","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib77","first-page":"279","article-title":"Evaluation of voriconazole oral dosage in Japan","volume":"67","author":"Hamada","year":"2014","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.jiac.2024.10.003_bib78","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/jac\/dkaa098","article-title":"Voriconazole: an audit of hospital-based dosing and monitoring and evaluation of the predictive performance of a dose-prediction software package","volume":"75","author":"Chaudhri","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib79","article-title":"Effectiveness and safety of the simulation-based first-dose design of voriconazole","volume":"27","author":"Umemura","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib80","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/00912700222011445","article-title":"Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study","volume":"42","author":"Lazarus","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.003_bib81","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014","volume":"44","author":"Chau","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.jiac.2024.10.003_bib82","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","article-title":"Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"97","author":"Mellinghoff","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jiac.2024.10.003_bib83","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Br\u00fcggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.003_bib84","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/bcp.16004","article-title":"Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: a multicentre retrospective study","volume":"90","author":"Kato","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.003_bib85","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/myc.13639","article-title":"Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients","volume":"66","author":"Hanai","year":"2023","journal-title":"Mycoses"},{"key":"10.1016\/j.jiac.2024.10.003_bib86","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/bmc.383","article-title":"Direct injection HPLC micro method for the determination of voriconazole in plasma using an internal surface reversed-phase column","volume":"18","author":"P\u00e9hourcq","year":"2004","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.jiac.2024.10.003_bib87","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1248\/cpb.56.328","article-title":"Determination of the antifungal agent voriconazole in human plasma using a simple column-switching high-performance liquid chromatography and its application to a pharmacokinetic study","volume":"56","author":"Nakagawa","year":"2008","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.jiac.2024.10.003_bib88","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jpba.2009.06.030","article-title":"Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection","volume":"50","author":"Gordien","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jiac.2024.10.003_bib89","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/jof8101035","article-title":"High-performance liquid chromatography for ultra-simple determination of plasma voriconazole concentration","volume":"8","author":"Yasu","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.jiac.2024.10.003_bib90","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3389\/fphar.2020.00505","article-title":"The impact of plasma protein binding characteristics and unbound concentration of voriconazole on its adverse drug reactions","volume":"11","author":"Yuan","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.003_bib91","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/FTD.0000000000000799","article-title":"Population pharmacokinetics of voriconazole in patients with invasive aspergillosis: serum albumin level as a novel marker for clearance and dosage optimization","volume":"42","author":"Chantharit","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2024.10.003_bib92","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.003_bib93","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2024.10.003_bib94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/11319340-000000000-00000","article-title":"Pharmacokinetic\/pharmacodynamic profile of posaconazole","volume":"49","author":"Li","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2024.10.003_bib95","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2024.10.003_bib97","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FTD.0b013e31823cef77","article-title":"Posaconazole serum level on day 2 predicts steady state posaconazole serum level","volume":"34","author":"Green","year":"2012","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2024.10.003_bib98","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12879-018-3055-3","article-title":"Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.003_bib99","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.cmi.2020.06.007","article-title":"How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)","volume":"26","author":"Arendrup","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2024.10.003_bib100","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/14740338.2022.2047177","article-title":"Hepatic safety of the antifungal triazole agent posaconazole: characterization of adverse event reports in a manufacturer's safety database","volume":"21","author":"O'Flynn","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jiac.2024.10.003_bib101","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad079","article-title":"Association of adverse effects with high serum posaconazole concentrations","volume":"61","author":"Jensen","year":"2023","journal-title":"Med Mycol"},{"key":"10.1016\/j.jiac.2024.10.003_bib102","first-page":"1","article-title":"A randomized, active-controlled, open-label, comparative study to assess the safety and efficacy of posaconazole in Japanese subjects with deep-seated fungal infection","volume":"61","author":"Kohno","year":"2020","journal-title":"Jpn J Med Mycol"},{"key":"10.1016\/j.jiac.2024.10.003_bib103","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02629-18","article-title":"No dose adjustment for isavuconazole based on age or sex","volume":"63","author":"Desai","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib104","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01728-19","article-title":"Population pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients","volume":"64","author":"Wu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib105","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/jcph.2212","article-title":"Population pharmacokinetics, exposure-safety, and probability of target attainment analyses for isavuconazole in Japanese patients with deep-seated mycoses","volume":"63","author":"Shirae","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.003_bib106","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/cpdd.376","article-title":"Two Phase 1, open-label, mass balance studies to determine the pharmacokinetics of 14 C-labeled isavuconazonium sulfate in healthy male volunteers","volume":"7","author":"Townsend","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jiac.2024.10.003_bib107","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2024.10.003_bib108","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib109","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/jac\/dkae088","article-title":"Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions","volume":"79","author":"Bergmann","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib110","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1128\/AAC.02819-15","article-title":"Population pharmacokinetics of isavuconazole from Phase 1 and Phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus and other filamentous fungi","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib111","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00585-18","article-title":"Isavuconazole concentration in real-world practice: consistency with results from clinical trials","volume":"62","author":"Andes","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib112","doi-asserted-by":"crossref","first-page":"e01511","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis","volume":"65","author":"Kosmidis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.10.003_bib113","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3314\/mmj.24.005","article-title":"Optimized antifungal therapy for chronic pulmonary aspergillosis","volume":"65","author":"Yagi","year":"2024","journal-title":"Med Mycol J"},{"key":"10.1016\/j.jiac.2024.10.003_bib114","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3314\/mmj.22.003","article-title":"Antifungal stewardship task shifting required of pharmacists","volume":"63","author":"Ebihara","year":"2022","journal-title":"Med Mycol J"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:47:57Z","timestamp":1738928877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24002769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1341321X24002769"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.10.003","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of azole antifungal agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102535"}}